References
[1]. Favipiravir in Covid-19 International Journal of Progressive
Sciences and Technologies (IJPSAT) Vol. 19 No. 2 March 2020, pp. 143-145
[2]. Report on the Deliberation Results of Avigan Tablet 200 mg
(Favipiravir), Pharmaceuticals and Medical Devices Agency (PMDA),
04.03.2014 https://www.pmda.go.jp/files/000210319.pdf
[3]. Cai, Q, Yang M, Liu D, Chen J, Shu D, Xia J et al. Experimental
Treatment with Favipiravir for COVID- 19: An Open-Label Control Study.
Engineering, in press, avaible online 16.04.2020.
[4]. Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, Chen S, et al.
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial.
MedRxiv 2020
[5]. Guideline on The Investigation of Bioequivalence.
CPMP/EWP/QWP/1401/98 Rev.1/Corr., London, EMA, 20 January 2010.
[6]. Guidance for Industry. Bioavailability and bioequivalence
studies for orally administered drug products- General Considerations.
FDA, CDER, March 2014.
[7]. The Guidance for GCP, published by the Ministry of Health of
Turkey. Circular, 13.11.2015.
[8]. Guideline on Bioanalytical Method Validation,
EMEA/CHMP/EWP/192217/2009 Rev.1 Corr.2, London, 21 July 2011.